You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Poor effect of guideline-based treatment of restless legs syndrome in clinical practice
  1. Richard J Davenport
  1. Correspondence to Dr Richard J Davenport, Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, UK; rjd{at}skull.dcn.ed.ac.uk

https://doi.org/10.1136/jnnp.2010.224022

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinicians have long recognised the gap between the impressive results of treatments in published randomised controlled trials (RCTs), and what can be achieved with those same treatments in practice. This leads to doubt—am I using the treatment correctly, on the right patients? The study by Godau et al1 highlights this disparity (see page 1390).

    In their observational study, they reported the effect of applying guideline-based treatments to 100 patients with restless legs syndrome (RLS) over 12 months. Although 90% of patients reported a subjective reduction in their RLS symptoms with dopaminergic drugs, this did not translate into improvements in quality of life or an RLS-specific rating score; this, …

    View Full Text

    Footnotes

    • Linked articles 211417.

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles